文献速递肿瘤 PET/CT

18F-FDG PET/CT评估外周T细胞淋巴瘤骨髓受累的诊断与预后价值

Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-Cell Lymphoma.
PubMed 文献 · Clin Nucl Med · 2019-01-01

28例确认BM受累者中BMB检出17例、PET/CT检出25例;66例BMB阴性者中11例PET/CT检出BM受累且无进展生存与总生存显著更短。基于PET/CT联合BMB的IPI分组倾向优于传统BMB-based IPI。

要点

  • PET/CT对PTCL骨髓受累的敏感性高于骨髓活检(25/28 vs 17/28)。
  • 骨髓活检阴性者中PET/CT检出骨髓受累者预后显著更差。
  • PET/BMB联合评估的IPI倾向优于传统骨髓活检IPI。

核心结论

  • PET/CT对PTCL骨髓受累的敏感性高于骨髓活检,且可识别骨髓活检阴性但预后不良的高危患者。
  • PET/CT联合骨髓活检可能改善PTCL现有预后分层策略。

研究设计与样本

  • 骨髓受累诊断依据骨髓组织学阳性或随访PET/CT骨髓异常消失且治疗有效。

主要发现

  • 28例确认骨髓受累患者中,骨髓活检检出17例,PET/CT检出25例。
  • 66例骨髓组织学阴性患者中,11例PET/CT检出骨髓受累,其无进展生存和总生存显著短于无骨髓受累者。
  • 基于髂嵴骨髓活检组织学联合PET/CT的PET/BMB-based IPI倾向优于传统BMB-based IPI。

关键数值与推荐

  • 骨髓受累确认标准:骨髓组织学阳性,或随访PET/CT骨髓异常消失并伴治疗有效。
  • 骨髓活检与PET/CT检出骨髓受累例数分别为17例和25例(共28例确认受累)。

临床怎么用

  • PTCL初诊评估骨髓受累时可考虑PET/CT,以补充骨髓活检的敏感性不足。
  • 骨髓活检阴性但PET/CT提示骨髓受累者应按高危管理并加强预后监测。

局限性

  • 回顾性研究设计。
  • PET/BMB-based IPI仅显示倾向优于传统IPI,未报告统计学比较结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: No study has analyzed a sizeable cohort that comprised solely peripheral T-cell lymphoma (PTCL) patients for the diagnostic and prognostic performance of F-FDG PET/CT for bone marrow (BM) involvement. This study aimed to investigate the utility of PET/CT for the identification of BM involvement and to explore its prognostic relevance in patients with PTCL. METHODS: Eighty-three consecutive patients with newly diagnosed PTCL were enrolled in this retrospective study. The diagnosis of BM involvement was confirmed on the basis of positive BM histology or disappearance of marrow abnormalities on follow-up PET/CT concurrently with a successful treatment response. RESULTS: Of 28 patients with confirmed BM involvement, BM biopsy (BMB) and PET/CT detected an involvement in 17 and 25 patients. Among 66 patients with negative BM histology, 11 patients had BM involvement detected by PET/CT and furthermore showed significantly shorter progression-free and overall survival than patients without BM involvement. We recategorized the International Prognostic Index (IPI) risk groups based on the presence of BM involvement using the combined assessment of iliac crest marrow biopsy histology and PET/CT (PET/BMB-based IPI). PET/BMB-based IPI tended to perform better than conventional BMB-based IPI. CONCLUSIONS: This study included the largest population of PTCL patients for PET/CT evaluation of BM involvement so far. PET/CT exhibited a higher sensitivity for BM involvement than BMB. Furthermore, BM assessment using PET/CT identified patients at high risk of disease progression and mortality among those with negative BM histology, suggesting that PET/CT may have a potential to improve existing prognostic strategies in PTCL.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Abe Y, Kitadate A, Usui Y, et al. Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-Cell Lymphoma. Clin Nucl Med. 2019. PMID: 30889000. doi:10.1097/RLU.0000000000002516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。